Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Multifaceted Role of microRNA-10b (miR-10b) in Glioblastoma: From Oncogenic Driver to Therapeutic Target.

Cells·2026
Same author

Template-Directed RIG-I Agonist Assembly for Image-guided Targeted Cancer Immunotherapy.

Molecular imaging and biology·2026
Same author

Nanotherapy Targeting miR-10b Improves Survival in Orthotopic Glioblastoma Models.

Journal of functional biomaterials·2026
Same author

Image-guided In Vivo Tracking of Transplanted Distal Lung Epithelial Progenitor Cells for Pulmonary Fibrosis Using Magnetic Particle Imaging.

Journal of visualized experiments : JoVE·2025
Same author

miR-10b as a Clinical Marker and a Therapeutic Target for Metastatic Breast Cancer.

Technology in cancer research & treatment·2025
Same author

Wearable Surface Electromyography System to Predict Freeze of Gait in Parkinson's Disease Patients.

Sensors (Basel, Switzerland)·2024

Related Experiment Video

Updated: Jun 26, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Development of PSMA-Targeted Liposomal Zinc for Prostate Cancer Therapy.

Sujan Kumar Mondal1,2, Elizabeth Kenyon1,2, Alexander L Klibanov3

  • 1Precision Health Program, Michigan State University, 766 Service Road, East Lansing, MI 48824, USA.

Nanomaterials (Basel, Switzerland)
|June 25, 2026
PubMed
Summary

Researchers developed targeted liposomes (Zn-TL) to deliver zinc into prostate cancer cells, restoring zinc levels and reducing tumor growth. This approach shows promise for early-stage prostate cancer treatment by targeting metabolic reprogramming.

Keywords:
liposomal deliveryprostate cancerprostate-specific membrane antigen (PSMA)zinc

More Related Videos

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Related Experiment Videos

Last Updated: Jun 26, 2026

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells
09:34

Uptake of New Lipid-coated Nanoparticles Containing Falcarindiol by Human Mesenchymal Stem Cells

Published on: February 9, 2019

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles
09:56

Preparation and Characterization of Lipophilic Doxorubicin Pro-drug Micelles

Published on: August 2, 2016

Area of Science:

  • Biochemistry
  • Nanotechnology
  • Oncology

Background:

  • Normal prostate cells accumulate zinc, crucial for metabolism and proliferation.
  • Prostate cancer cells exhibit reduced zinc uptake, leading to metabolic changes that drive tumor growth.
  • Targeted zinc delivery is a potential therapeutic strategy, but overcoming zinc transporter downregulation is challenging.

Purpose of the Study:

  • To develop and evaluate prostate-specific membrane antigen (PSMA)-targeted, zinc-loaded liposomes (Zn-TL) for selective intracellular zinc delivery in prostate cancer.
  • To assess the efficacy of Zn-TL in vitro and in vivo for prostate cancer treatment.

Main Methods:

  • Formulation of nanoscale zinc-loaded liposomes (Zn-TL) with PSMA targeting.
  • In vitro studies involving prostate cancer cells to assess uptake, cytotoxicity, and apoptosis.
  • In vivo studies in mice with PSMA-positive tumors to evaluate circulation time, tumor accumulation, and tumor growth delay.

Main Results:

  • Zn-TL exhibited uniform size, low polydispersity, and stable zinc retention.
  • Zn-TL demonstrated receptor-mediated uptake in prostate cancer cells, leading to increased cytotoxicity and apoptosis.
  • In vivo studies showed prolonged circulation and tumor accumulation of Zn-TL, with delayed tumor growth in early/intermediate stages.

Conclusions:

  • PSMA-targeted, zinc-loaded liposomes (Zn-TL) enable selective intracellular zinc delivery to prostate tumors.
  • Zn-TL shows potential as a platform for metabolic intervention in prostate cancer, particularly in earlier disease stages.
  • Combination strategies may enhance Zn-TL efficacy in advanced prostate cancer.